Archivos de Bronconeumología Archivos de Bronconeumología
Arch Bronconeumol 2012;48 Supl 1:2-58 - Vol. 48 DOI: 10.1016/S0300-2896(12)70035-2
Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC)
Clinical Practice Guideline for the Diagnosis and Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) – Spanish Guideline for COPD (GesEPOC)
Grupo de Trabajo de GesEPOC, Task Force of GesEPOC
El Texto completo solo está disponible en PDF
Bibliografía
1.
M. Miravitlles,M. Calle,J.J. Soler-Cataluña
Clinical phenotypes of COPD. Identification, definition and implications for guidelines
Arch Bronconeumol, 48 (2012), pp. 86-98 http://dx.doi.org/10.1016/j.arbres.2011.10.007
2.
J.B. Soriano,J. Zielinski,D. Price
Screening for and early detection of chronic obstructive pulmonary disease
3.
Estrategia en EPOC del Sistema Nacional de Salud
Plan de Calidad para el Sistema Nacional de Salud
Ministerio de Sanidad y Política Social, (2009)
4.
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Disponible en: http://www.goldcopd.org.
5.
G. Peces-Barba,J.A. Barberà,A. Agustí,C. Casanova,A. Casas,J.L. Izquierdo
Guía clínica de diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y Asociación Latinoamericana del Tórax (ALAT)
Arch Bronconeumol, 44 (2008), pp. 271-281
6.
Grupo de trabajo de la guía de práctica clínica sobre atención integral al paciente con enfermedad pulmonar obstructiva crónica (EPOC). Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y Sociedad Española de Medicina de Familia (semFYC); 2010.
7.
M.K. Han,A. Agustí,P.M. Calverley,B.R. Celli,G. Criner,J.L. Curtis
Chronic obstructive pulmonary disease phenotypes. The future of COPD
Am J Respir Crit Care Med, 182 (2010), pp. 598-604 http://dx.doi.org/10.1164/rccm.200912-1843CC
8.
M. Miravitlles
Tratamiento individualizado de la EPOC: una propuesta de cambio
Arch Bronconeumol, 45 (2009), pp. 27-34 http://dx.doi.org/10.1016/S0300-2896(09)72952-7
9.
Grupo de trabajo GESEPOC
Hacia un nuevo enfoque en el tratamiento de la EPOC. La Guía Española de la EPOC (GESEPOC)
Arch Bronconeumol, 47 (2011), pp. 379-381 http://dx.doi.org/10.1016/j.arbres.2011.05.008
10.
D. Anderson,W. MacNee
Targeted treatment in COPD: a multi-system approach for a multi-system disease
Int J Chron Obst Pulm Dis, 4 (2009), pp. 321-335
11.
Manual Metodológico para la elaboración de guías de práctica clínica del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo; 2007. Disponible en: http://www.guiasalud.es/emanuales/elaboracion/documentos/Manual%20metodologico%20%20Elaboracion%20GPC%20en%20el%20SNS.pdf.
12.
G. Guyatt,A.D. Oxman,E.A. Akl,R. Kunz,G. Vist,J. Brozek
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
J Clin Epidemiol, 64 (2011), pp. 383-394 http://dx.doi.org/10.1016/j.jclinepi.2010.04.026
13.
M. Marzo Castillejo,A. Montaño Barrientos
El sistema GRADE para la toma de decisiones clínicas y la elaboración de recomendaciones y guías de práctica clínica
Aten Primaria, 39 (2007), pp. 457-460
14.
G.H. Guyatt,A.D. Oxman,R. Kunz,J. Woodcock,J. Brozek,M. Helfand
GRADE guidelines: 8. Rating the quality of evidenced indirectness
J Clin Epidemiol, 64 (2011), pp. 1303-1310 http://dx.doi.org/10.1016/j.jclinepi.2011.04.014
15.
J. Bousquet,J. Kiley,E.D. Bateman,G. Viegi,A.A. Cruz,N. Khaltaev
Prioritised research agenda for prevention and control of chronic respiratory diseases
Eur Respir J, 36 (2010), pp. 995-1001 http://dx.doi.org/10.1183/09031936.00012610
16.
A.S. Buist,M.A. McBurnie,W.M. Vollmer,S. Gillespie,P. Burney,D.M. Mannino
International variation in the prevalence of COPD (the BOLD study): a populationbased prevalence study
17.
R.J. Halbert,J.L. Natoli,A. Gano,E. Badamgarav,A.S. Buist,D.M. Mannino
Global burden of COPD: systematic review and meta-analysis
Eur Respir J, 28 (2006), pp. 523-532 http://dx.doi.org/10.1183/09031936.06.00124605
18.
K. Atsou,C. Chouaid,G. Hejblum
Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review
19.
V.S. Sobradillo-Peña,M. Miravitlles,R. Gabriel,C.A. Jiménez- Ruiz,C. Villasante,J.F. Masa
Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study
Chest, 118 (2000), pp. 981-989
20.
M. Miravitlles,M. Ferrer,A. Pont,J.L. Viejo,J.F. Masa,R. Gabriel
Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers
Respir Med, 99 (2005), pp. 985-995 http://dx.doi.org/10.1016/j.rmed.2005.01.012
21.
M. Miravitlles,J.B. Soriano,F. García-Río,L. Muñoz,E. Duran-Taulería,G. Sánchez
Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities
22.
J.B. Soriano,J. Ancochea,M. Miravitlles,F. García-Río,E. Duran,L. Muñoz
Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997–2007
Eur Respir J, 36 (2010), pp. 758-765 http://dx.doi.org/10.1183/09031936.00138409
23.
WHO. World health statistics 2008. Disponible en: http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf. 2010.
24.
Regidor E, Gutiérrez-Fisac JL, Alfaro M. Patrón de mortalidad en España, 2008. Madrid: Ministerio de Sanidad, Política Social e Igualdad, 2011. Disponible en: http://www.msc.es/ca/estadEstudios/estadisticas/estadisticas/estMinisterio/mortalidad/docs/Patrones_de_Mortalidad_en_Eaa_2008.pdf.
25.
Raziel: Mortalidad por todas las causas. Área de Análisis Epidemiológico y Situación de Salud. Disponible en: http://193.146.50.130/raziel.php.
26.
Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. Disponible en: http://www.msc.es/estadEstudios/estadisticas/cmbd.htm.
27.
Ministerio de Sanidad y Política Social. Plan de Calidad para el Sistema Nacional de Salud. Estrategia en EPOC del Sistema Nacional de Salud. Sanidad 2009. Ministerio de Sanidad y Política Social. Disponible en: http://www.msc.es/organizacion/sns/planCalidadSNS/docs/EstrategiaEPOCSNS.pdf.
28.
M. Miravitlles,C. Murio,T. Guerrero,R. Gisbert,on behalf of the DAFNE study group
Costs of chronic bronchitis and COPD. A one year follow-up study
Chest, 123 (2003), pp. 784-791
29.
J.J. Soler-Cataluña,M. Calle,B.G. Cosio,J.M. Marín,E. Monso,I. Alfageme
Estándares de calidad asistencial en la EPOC
Arch Bronconeumol, 45 (2009), pp. 361-362
30.
B.R. Celli,W. MacNee
ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
Eur Respir J, 23 (2004), pp. 932-946
31.
B.R. Celli,N.E. Thomas,J.A. Anderson,G.T. Ferguson,C.R. Jenkins,P.W. Jones
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 178 (2008), pp. 332-338 http://dx.doi.org/10.1164/rccm.200712-1869OC
32.
B.D. Patel,H.O. Coxson,S.G. Pillai,A.G.N. Agustí,P.M.A. Calverley,C.F. Donner
Airway wall thickening and emphysema show independente familial aggregation in chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 178 (2008), pp. 500-505 http://dx.doi.org/10.1164/rccm.200801-059OC
33.
F. Martínez-García,J.J. Soler-Cataluña,Y. Donat,P. Catalán,M. Agramunt,V. Ballestin
Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients
Chest, 140 (2011), pp. 1130-1137 http://dx.doi.org/10.1378/chest.10-1758
34.
J. Garcia-Aymerich,F.P. Gómez,M. Benet,E. Farrero,X. Basagaña,A. Gayete
Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) phenotypes
35.
R. Vidal,I. Blanco,F. Casas,R. Jardí,M. Miravitlles
Comité del Registro Nacional de Pacientes con Déficit de Alfa-1-antitripsina. Normativa SEPAR: Diagnóstico y tratamiento del déficit de alfa-1-antitripsina
Arch Bronconeumol, 42 (2006), pp. 645-659
36.
J.R. Hurst,J. Vestbo,A. Anzeto,N. Locantore,H. Müllerova,R. Tal-Singer
Susceptibility to exacerbation in chronic obstructive pulmonary disease
N Engl J Med, 363 (2010), pp. 1128-1138 http://dx.doi.org/10.1056/NEJMoa0909883
37.
J.J. Soler Cataluña,M.A. Martínez García,P. Catalán Serra
The frequent exacerbator. A new phenotype in COPD?
Hot Topics Respir Med, 6 (2011), pp. 7-12
38.
J.K. Quint,G.C. Donaldson,J.R. Hurst,J.J.P. Goldring,T.R. Seemungal,J.A. Wedzicha
Predictive accuracy of patient-reported exacerbation frequency in COPD
Eur Respir J, 37 (2011), pp. 501-507 http://dx.doi.org/10.1183/09031936.00035909
39.
M. Bafadhel,S. McKenna,S. Terry,V. Mistry,C. Reid,P. Haldar
Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers
Am J Respir Crit Care Med, 184 (2011), pp. 662-671 http://dx.doi.org/10.1164/rccm.201104-0597OC
40.
P.G. Gibson,J.L. Simpson
The overlap syndrome of asthma and COPD: what are its features and how important is it?
41.
M. Contoli,S. Baraldo,B. Marku,P. Casolari,J.A. Marwick,G. Turato
Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: a 5-year follow-up
J Allergy Cin Immunol, 125 (2010), pp. 830-837
42.
L.P. Boulet,C. Lemiere,F. Archambault
Smoking and asthma: clinical and radiological features, lung function, and airway inflammation
43.
D.E. O’Donnell,S. Aaron,J. Bourbeau,P. Hernandez,D.D. Marciniuk,M. Balter
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease: 2007 update
Can Respir J, 14 (2007), pp. B:5B-B:B32
44.
A. Nagai,H. Aizawa,K. Aoshiba,K. Asano,K. Hirata,M. Ichinose
Guidelines for the diagnosis and treatment of COPD. The Japanese Respiratory Society
3rd, Medical Review Co. Ltd, (2009)
45.
R. De Marco,S. Accordini,I. Cerveri,A. Corsico,J.M. Antó,N. Künzli
Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm
Am J Respir Crit Care Med, 175 (2007), pp. 32-39 http://dx.doi.org/10.1164/rccm.200603-381OC
46.
M. Miravitlles
The overlap síndrome between asthma and COPD: implications for management
Hot Topics Respir Med, 16 (2011), pp. 15-20
47.
M. Hardin,E.K. Silverman,R.G. Barr,N.H. Hansel,J.D. Schroeder,B.J. Make
The clinical features of the overlap between COPD and asthma
48.
J.B. Soriano,K.J. Davis,B. Coleman,G. Visick,D. Mannino,N.B. Pride
The proportional Venn diagram of obstructive lung disease
Chest, 124 (2003), pp. 474-481
49.
American Thoracic Society
Chronic bronchitis, asthma, and pulmonary emphysema, a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases
Am Rev Respir Dis, 85 (1962), pp. 762-768
50.
E. Prescott,P. Lange,J. Vestbo
Chronic mucus hypersecretion in COPD and death from pulmonary infection
Eur Respir J, 8 (1995), pp. 1333-1338
51.
M. Miravitlles
Cough and sputum production as risk factors for poor outcomes in patients with COPD
Respir Med, 105 (2011), pp. 1118-1128 http://dx.doi.org/10.1016/j.rmed.2011.02.003
52.
M. Montes de Oca,R.J. Halbert,M.V. López,R. Pérez-Padilla,C. Tálamo,D. Moreno
Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study
53.
V. Kim,M.K. Han,G.B. Vance,B.J. Make,J.D. Newel,J.E. Hokanson
The chronic bronchitic phenotype of COPD. An analysis of the COPDGene study
Chest, 140 (2011), pp. 626-633 http://dx.doi.org/10.1378/chest.10-2948
54.
I.S. Patel,I. Vlahos,T.M.A. Wilkinson,S.J. Lloyd-Owen,G.C. Donaldson,M. Wilks
Bronchiectasis, exacerbation índices, and inflammation in chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 170 (2004), pp. 400-407 http://dx.doi.org/10.1164/rccm.200305-648OC
55.
C. Casanova,C. Cote,J.P. De Torres,A. Aguirre-Jaime,J.M. Marín,V. Pinto-Plata
Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 171 (2005), pp. 591-597 http://dx.doi.org/10.1164/rccm.200407-867OC
56.
T.B. Grydeland,E. Thorsen,A. Dirksen,R. Jensen,H.O. Coxson,S.G. Pillai
Quantitative CT measures of emphysema and airway wall thickness are related to D(L)CO
57.
M.K. Han,E.A. Kazerooni,D.A. Lynch,L.X. Liu,S. Murray,J.L. Curtis
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes
Radiology, 261 (2011), pp. 274-282 http://dx.doi.org/10.1148/radiol.11110173
58.
M. Nishimura,H. Makita,K. Nagai,S. Konno,Y. Nasuhara,M. Hasegawa
Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 185 (2012), pp. 44-52 http://dx.doi.org/10.1164/rccm.201106-0992OC
59.
N.C. Oswald,V.C. Medvei
Chronic bronchitis: the effect of cigarette-smoking
Lancet, 269 (1955), pp. 843-844
60.
D. Anderson,B.G. Ferris Jr.
Role of tobacco smoking in the causation of chronic respiratory disease
N Engl J Med, 267 (1962), pp. 787-794 http://dx.doi.org/10.1056/NEJM196210182671601
61.
C. Fletcher,R. Peto
The natural history of chronic airflow obstruction
Br Med J, 1 (1977), pp. 1645-1648
62.
R. Kohansal,P. Martinez-Camblor,A. Agusti,A.S. Buist,D.M. Mannino,J.B. Soriano
The natural history of chronic airflow obstruction revisited: an analysis of the Framingham off spring cohort
Am J Respir Crit Care Med, 180 (2009), pp. 3-10 http://dx.doi.org/10.1164/rccm.200901-0047OC
63.
A. Lokke,P. Lange,H. Scharling,P. Fabricius,J. Vestbo
Developing COPD: a 25 year follows up study of the general population
64.
Encuesta de salud de España. Disponible en: http://www.msc.es.
65.
S.S. Salvi,P.J. Barnes
Chronic obstructive pulmonary disease in nonsmokers
66.
M.S. Jaakkola,J.J. Jaakkola
Effects of environmental tobacco smoke on the respiratory health of adults
Scand J Work Environ Health, 28 (2002), pp. 52-70
67.
M.L. Larsson,H.M. Loit,M. Meren,J. Põlluste,A. Magnusson,K. Larsson
Passive smoking and respiratory symptoms in the FinEsS Study
Eur Respir J, 21 (2003), pp. 672-676
68.
P. Yin,C.O. Jiang,K.K. Cheng,T.H. Lam,K.H. Lam,M.R. Miller
Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study
69.
S.Y. Ho,T.H. Lam,S.F. Chung,T.P. Lam
Cross-sectional and prospective associations between passive smoking and respiratory symptoms at the workplace
Ann Epidemiol, 17 (2007), pp. 126-131 http://dx.doi.org/10.1016/j.annepidem.2006.06.010
70.
F.J. González Barcala,B. Takkouche,L. Valdés,E. Temes,R. Leis,R. Cabanas
Tabaquismo parental y función pulmonar en niños y adolescentes
Arch Bronconeumol, 43 (2007), pp. 81-85
71.
C. Torres-Duque,D. Maldonado,R. Pérez-Padilla,M. Ezzati,G. Viegi
Forum of International Respiratory Studies (FIRS) Task Force on Health Effects of Biomass. Exposure biomass fuels and respiratory diseases: a review of the evidence
Proc Am Thorac Soc, 5 (2008), pp. 577 http://dx.doi.org/10.1513/pats.200707-100RP
72.
G. Hu,Y. Zhou,J. Tian,W. Yao,J. Li,B. Li
Risk of COPD from exposure to biomass smoke: a metaanalysis
73.
O.P. Kurmi,S. Semple,P. Simkhada,W.C. Smith,J.G. Ayres
COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis
74.
J.Y. Po,J.M. FitzGerald,C. Carlsten
Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis
75.
M. Orozco-Levi,J. García-Aymerich,J. Villar,A. Ramírez-Sarmiento,J.M. Antó,J. Gea
Wood smoke exposure and risk of chronic obstructive pulmonary disease
Eur Respir J, 27 (2006), pp. 542-546 http://dx.doi.org/10.1183/09031936.06.00052705
76.
M.D. Eisner,N. Anthonisen,D. Coultas,N. Kuenzli,R. Pérez-Padilla,D. Postma
Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 182 (2010), pp. 693-718 http://dx.doi.org/10.1164/rccm.200811-1757ST
77.
M.A. Arbex,G.M. De Souza Conceição,S.P. Cendon,F.F. Arbex,A.C. Lopes,E.P. Moysés
Urban air pollution and COPD-related emergency room visits
J Epidemiol Community Health, 63 (2009), pp. 777-783 http://dx.doi.org/10.1136/jech.2008.078360
78.
Z.J. Andersen,M. Hvidberg,S.S. Jensen,M. Ketzel,S. Loft,M. Sørensen
Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study
Am J Respir Crit Care Med, 183 (2011), pp. 455-461 http://dx.doi.org/10.1164/rccm.201006-0937OC
79.
EURAD [acceso 18 de mayo de 2011]. Disponible en: http://www.eurad.unikoeln.de/.
80.
L. Rushton
Occupational causes of chronic obstructive pulmonary disease
Rev Environ Health, 22 (2007), pp. 195-212
81.
E. Rodríguez,J. Ferrer,S. Martí,J.P. Zock,E. Plana,F. Morell
Impact of occupational exposure on severity of COPD
Chest, 134 (2008), pp. 1237-1243 http://dx.doi.org/10.1378/chest.08-0622
82.
K.B. Lam,C.Q. Jiang,R.E. Jordan,M.R. Miller,W.S. Zhang,K.K. Cheng
Smoking and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study
Chest, 137 (2010), pp. 593-600 http://dx.doi.org/10.1378/chest.09-1435
83.
A.M.B. Menezes,P.C. Hallal,R. Perez-Padilla,J.R.B. Jardim,A. Muiño,M.V. Lopez
Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America
Eur Respir J, 30 (2006), pp. 1180-1185 http://dx.doi.org/10.1183/09031936.00083507
84.
Chronic obstructive pulmonary disease: risk factors and risk reduction [acceso julio 2009]. Disponible en: http://www.uptodate.com/online/.
85.
T. Kohnlein,T. Welte
Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment
86.
M. Miravitlles,C. Herr,I. Ferrarotti,R. Jardi,F. Rodriguez-Frias,M. Luisetti
Laboratory testing of individuals with severe AAT deficiency in three European centres
Eur Respir J, 35 (2010), pp. 960-968 http://dx.doi.org/10.1183/09031936.00069709
87.
D.M. Mannino,A.S. Buist
Global burden of COPD: risk factors, prevalence, and future trends
88.
N. Roche,R. Marthan,P. Berger,A. Chambellan,P. Chanez,B. Aguilaniu
Beyond corticosteroids: future prospects in the management of inflammation in COPD
Eur Respir Rev, 20 (2011), pp. 175-182 http://dx.doi.org/10.1183/09059180.00004211
89.
I.A. Yang,V. Relan,C.M. Wright,M.R. Davidson,K.B. Sriram,S.M. Savarimuthu Francis
Common pathogenic mechanisms and pathways in the development of COPD and lung cancer
Expert Opin Ther Targets, 15 (2011), pp. 439-456 http://dx.doi.org/10.1517/14728222.2011.555400
90.
W.M. Chatila,B.M. Thomashow,O.A. Minai,G.J. Criner,B.J. Make
Comorbidities in chronic obstructive pulmonary disease
Proc Am Thorac Soc, 5 (2008), pp. 549-555 http://dx.doi.org/10.1513/pats.200709-148ET
91.
P. Barnes,B.R. Celli
Systemic manifestations and comorbidities in COPD
Eur Respir J, 33 (2009), pp. 1165-1185 http://dx.doi.org/10.1183/09031936.00128008
92.
J.B. Soriano,J. Sauleda
Chapter 12. How the COPD patient should be assessed for co-morbidities
Clinical management of chronic obstructive lung disease, 2nd,
93.
P.M. Calverley,J.A. Anderson,B. Celli,G.T. Ferguson,C. Jenkins,P.W. Jones
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
N Engl J Med, 356 (2007), pp. 775-789 http://dx.doi.org/10.1056/NEJMoa063070
94.
J.B. Soriano,G.T. Visick,H. Muellerova,N. Payvandi,A.L. Hansell
Patterns of comorbidities in newly diagnosed COPD and asthma in primary care
Chest, 128 (2005), pp. 2099-2107 http://dx.doi.org/10.1378/chest.128.4.2099
95.
D.M. Mannino,D. Thorn,A. Swensen,F. Holguin
Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease
Eur Respir J, 32 (2008), pp. 962-969 http://dx.doi.org/10.1183/09031936.00012408
96.
P. Almagro,F. López García,F.J. Cabrera,L. Montero,D. Morchón,J. Díez
Study of the comorbidities in hospitalized patients due to decompensated chronic obstructive pulmonary disease attended in the Internal Medicine Services. ECCO Study
Rev Clin Esp, 210 (2010), pp. 101-108 http://dx.doi.org/10.1016/j.rce.2009.12.002
97.
J. Finkelstein,E. Cha,S.M. Scharf
Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
Int J Chron Obstruct Pulmon Dis, 4 (2009), pp. 337-349
98.
J.R. Feary,L.C. Rodrigues,C.J. Smith,R.B. Hubbard,J.E. Gibson
Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care
99.
G.C. Donaldson,J.R. Hurst,C.J. Smith,R.B. Hubbard,J.A. Wedzicha
Increased risk of myocardial infarction and stroke following exacerbation of COPD
Chest, 137 (2010), pp. 1091-1097 http://dx.doi.org/10.1378/chest.09-2029
100.
F.H. Rutten,M.J. Cramer,D.E. Grobbee,A.P. Sachs,J.H. Kirkels,J.W. Lammers
Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease
Eur Heart J, 26 (2005), pp. 1887-1894 http://dx.doi.org/10.1093/eurheartj/ehi291
101.
M.L. Render,A.S. Weinstein,A.S. Blaustein
Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease
Chest, 107 (1995), pp. 162-168
102.
P. Almagro,E. Calbo,A. Ochoa de Echagüen,B. Barreiro,S. Quintana,J.L. Heredia
Mortality after hospitalization for COPD
Chest, 121 (2002), pp. 1441-1448
103.
R.G. Barr,D.A. Bluemke,F.S. Ahmed,J.J. Carr,P.L. Enright,E.A. Hoffman
Percent emphysema, airflow obstruction, and impaired left ventricular filling
N Engl J Med, 362 (2010), pp. 217-227 http://dx.doi.org/10.1056/NEJMoa0808836
104.
R.P. Young,R.J. Hopkins,T. Christmas,P.N. Black,P. Metcalf,G.D. Gamble
COPD prevalence is increased in lung cancer, independent of age, sex and smoking history
Eur Respir J, 34 (2009), pp. 380-386 http://dx.doi.org/10.1183/09031936.00144208
105.
D.R. Brenner,J.R. McLaughlin,R.J. Hung
Previous lung diseases and lung cancer risk: a systematic review and meta-analysis
106.
A.M. Yohannes,T.G. Willgoss,R.C. Baldwin,M.J. Connolly
Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles
Int J Geriatr Psychiatry, 25 (2010), pp. 1209-1221 http://dx.doi.org/10.1002/gps.2463
107.
T.P. Ng,M. Niti,W.C. Tan,Z. Cao,K.C. Ong,P. Eng
Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life
Arch Intern Med, 167 (2007), pp. 60-67 http://dx.doi.org/10.1001/archinte.167.1.60
108.
E.M. Mortensen,L.A. Copeland,M.J. Pugh,M.I. Restrepo,R.M. De Molina,B. Nakashima
Impact of statins and ACE inhibitors on mortality after COPD exacerbations
109.
S. Salpeter,T. Ormiston,E. Salpeter
Betabloqueantes cardioselectivos para la enfermedad pulmonar obstructiva crónica (Revisión Cochrane traducida)
La Biblioteca Cochrane Plus, (2008),
110.
P.M. Short,S.I. Lipworth,D.H. Elder,S. Schembri,B.J. Lipworth
Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study
Br Med J, 10 (2011), pp. d2549
111.
M. Decramer,B. Celli,S. Kesten,T. Lystig,S. Mehra,D.P. Tashkin,UPLIFT investigators
Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial
112.
C.R. Jenkins,P.W. Jones,P.M. Calverley
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
113.
G.C. Donaldson,T.A.R. Seemugal,A. Bhowmik,J.A. Wedzicha
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
Thorax, 57 (2002), pp. 847-852
114.
J. Vestbo,E.D. Edwards,P.D. Scanlon,J.C. Yates,A. Agustí,P. Bakke
Changes in forced expiratory volume in 1 second over time in COPD
N Engl J Med, 365 (2011), pp. 1184-1192 http://dx.doi.org/10.1056/NEJMoa1105482
115.
S.I. Rennard,J.K. Stolel,K.C. Wilson
Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging, (2011),
116.
J. Sanchís Aldás,P. Casan Clarà,J. Castillo Gómez,N. Honzález Mangado,L. Palenciano Ballesteros,J. Roca Torrent
Normativa para la práctica de la espirometría forzada
Arch Bronconeumol, 25 (1989), pp. 132-142
117.
M. Monteagudo,T. Rodriguez-Blanco,J. Parcet,N. Peñalver,C. Rubio,M. Ferrer
Variabilidad en la realización de la espirometría y sus consecuencias en el tratamiento de la EPOC en Atención Primaria
Arch Bronconeumol, 47 (2011), pp. 226-233 http://dx.doi.org/10.1016/j.arbres.2010.10.009
118.
K. Naberan,C. De la Roza,M. Lamban,E. Gobartt,A. Martín,M. Miravitlles
Use of spirometry in the diagnosis and treatment of chronic obstructive pulmonary disease in Primary Care
Arch Bronconeumol, 42 (2006), pp. 638-644
119.
J.A. Hardie,A.S. Buist,W.M. Vollmer,I. Ellingsen,P.S. Bakke,O. Morkve
Risk of overdiagnosis of COPD in asymptomatic elderly never-smokers
Eur Respir J, 20 (2002), pp. 1117-1122
120.
B.R. Celli,R.J. Halbert,S. Isonaka,B. Schau
Population impact of different definitions of airway obstruction
Eur Respir J, 22 (2003), pp. 268-273
121.
R.A. Matthay,M.S. Niederman,H.P. Wiedemann
Cardiovascular-pulmonary interaction in chronic obstructive pulmonary disease with special reference to the pathogenesis and management of cor pulmonale
Med Clin North Am, 74 (1990), pp. 571
122.
R.G. Badgett,D.J. Tanaka,D.K. Hunt
Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone?
Am J Med, 94 (1993), pp. 188
123.
M. Miniati,S. Monti,J. Stolk,G. Mirarchi,F. Falaschi,R. Rabinovich
Value of chest radiography in phenotyping chronic obstructive pulmonary disease
Eur Respir J, 31 (2008), pp. 509-514 http://dx.doi.org/10.1183/09031936.00095607
124.
T.B. Grydeland,A. Dirksen,H.O. Coxson,T.M.L. Eagan,E. Thorsen,S.G. PIllai
Quantitative computed tomography measures of emphysema and airway Wall thickness are related to respiratory symptoms
Am J Respir Crit Care Med, 181 (2010), pp. 353-359 http://dx.doi.org/10.1164/rccm.200907-1008OC
125.
G. Mair,J. Maclay,J.J. Miller,D. MacAllister,M. Connell,J.T. Murchison
Airway dimensions in COPD: relationship with clinical variables
Respir Med, 104 (2010), pp. 1683-1690 http://dx.doi.org/10.1016/j.rmed.2010.04.021
126.
R. Yuan,J.C. Hogg,D.D. Sin
Prediction of the rate of decline in FEV1 in smokers using quantitative computed tomography
127.
A. Haruna,S. Muro,Y. Nakano,T. Ohara,Y. Hoshino,E. Ogawa
CT scan findings of emphysema predict mortality in COPD
Chest, 138 (2010), pp. 635-640 http://dx.doi.org/10.1378/chest.09-2836
128.
M. Vendrell,J. De Gracia,C. Olveira,M.A. Martínez,R. Girón,L. Máiz
Diagnóstico y tratamiento de las bronquiectasias
Arch Bronconeumol, 44 (2008), pp. 629-640
129.
M. John,S. Hoernig,W. Doehner,D.D. Okonko,C. Witt,S.D. Anker
Anemia and inflammation in COPD
130.
Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting
Bull World Health Organ, 75 (1997), pp. 397-415
131.
Vilaró J. Prueba de la marcha de los 6 minutos. En: Burgos Rincón F, Casan Clará P, coordinadores. Manual de procedimientos SEPAR n.° 4: Procedimientos de evaluación de la función pulmonar-II. Madrid: SEPAR; 2004. p. 100-13.
132.
H. Boushey,P. Enright,J. Samet
spirometry for chronic obstructive pulmonary disease case finding in primary care?
Am J Respir Crit Care Med, 172 (2005), pp. 1481-1486 http://dx.doi.org/10.1164/rccm.2509009
133.
T.J. Wilt,D. Niewoehner,C. Kim
Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Summary, Evidence Report/Technology Assessment: Number 121. AHRQ Publication Number 05-E017-1
Agency for Healthcare Research and Quality, (2005)
134.
M. Miravitlles,C. Llor,E. Calvo,S. Díaz,H. Díaz-Cuervo,N. González-Rojas
Validación de la versión traducida del chronic obstructive pulmonary disease-population screener (COPD-PS). Su utilidad y la del FEV1/FEV6 para el diagnóstico de EPOC
Med Clin (Barc), (2012),
135.
F.J. Martinez,A.E. Raczek,F.D. Seifer,C.S. Conoscenti,T.G. Curtice,T. D’Eletto
Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS)
136.
C.P. Van Schayck,J.M.C. Loozen,E. Wagena,R.P. Akkermans,G.J. Wesseling
Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study
Br Med J, 324 (2002), pp. 1370
137.
M.J. Rodríguez Nieto,J. Galán Gallego,M. Martín García,A. Batanero,E. García,G. Peces-Barba
Fiabilidad y facilidad de uso de un nuevo espirómetro portátil en el diagnóstico de la EPOC
Rev Patol Respir, 14 (2011), pp. 53-89
138.
J.Y. Jing,T.C. Huang,W. Cui,F. Xu,H.H. Shen
Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A meta-analysis
Chest, 135 (2009), pp. 991-998 http://dx.doi.org/10.1378/chest.08-0723
139.
C. Represas Represas,M. Botana Rial,V. Leiro Fernández,A.I. González Silva,V. Del Campo Pérez,A. Fernandez-Villar
Validación del dispositivo portátil COPD-6 para la detección de patologías obstructivas de la vía aérea
Arch Bronconeumol, 46 (2010), pp. 426-432 http://dx.doi.org/10.1016/j.arbres.2010.04.008
140.
J.J. Soler-Cataluña,B. Cosío,J.L. Izquierdo,J.L. López-Campos,J.M. Marín,R. Agüero
Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC
Arch Bronconeumol, (2012),
141.
M. Miravitlles,A. Marin,E. Monsó,S. Vilà,C. De la Roza,R. Hervás
Colour of sputum is a marker of bacterial colonization in COPD
142.
B. Burrows,R.H. Earle
Prediction of survival in patients with chronic airway obstruction
Am Rev Respir Dis, 99 (1969), pp. 865-871 http://dx.doi.org/10.1164/arrd.1969.99.6.865
143.
K. Nishimura,T. Izumi,M. Tsukino,T. Oga
en representación del Kansai COPD registry and research group in Japan. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD
Chest, 121 (2002), pp. 1434-1440
144.
V.M. Pinto-Plata,C. Cote,H. Cabral,J. Taylor,B.R. Celli
The 6-min walk distance: change over time and value as a predictor of survival in severe COPD
Eur Respir J, 23 (2004), pp. 28-33
145.
B.R. Celli,C.G. Cote,J.M. Marín,C. Casanova,M. Montes de Oca,R.A. Mendez
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease
N Engl J Med, 350 (2004), pp. 1005-1012 http://dx.doi.org/10.1056/NEJMoa021322
146.
K.C. Ong,A. Earnest,S.J. Lu
A Multidimensional grading system (BODE Index) as predictor of hospitalization for COPD
Chest, 128 (2005), pp. 3810-3816 http://dx.doi.org/10.1378/chest.128.6.3810
147.
L. An,Y.X. Lin,T. Yang,H. Zhang,X. Jiao,S. Zhang
Predictive validity of BODE index for anxious and depressive symptoms in patients with chronic obstructive pulmonary disease
Chin Med J, 123 (2010), pp. 1845-1851
148.
C.G. Cote,B.R. Celli
Pulmonary rehabilitation and the BODE index in COPD
Eur Respir J, 26 (2005), pp. 630-636 http://dx.doi.org/10.1183/09031936.05.00045505
149.
S. Imfeld,K.E. Bloch,W. Weder,E.W. Russi
The BODE index after lung volume reduction correlates with survival in COPD
150.
J.J. Soler-Cataluña,M.A. Martínez-García,L. Sánchez,M. Perpiña,P. Román
Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients
Respir Med, 103 (2009), pp. 692-699 http://dx.doi.org/10.1016/j.rmed.2008.12.005
151.
J.C. Bestall,E.A. Paul,R. Garrod,R. Garnham,P.W. Jones,J.A. Wedzicha
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease
Thorax, 54 (1999), pp. 581-586
152.
C. Esteban,J.M. Quintana,M. Aburto,J. Moraza,M. Egurrola,J. Pérez-Izquierdo
Impact of changes in physical activity on health-related quality of life among patients with COPD
Eur Respir J, 36 (2010), pp. 292-300 http://dx.doi.org/10.1183/09031936.00021409
153.
J. García-Aymerich,P. Lange,M. Benet,P. Schnohr,J.M. Antó
Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 175 (2007), pp. 458-463 http://dx.doi.org/10.1164/rccm.200607-896OC
154.
B. Waschki,A. Kirsten,O. Holz,K.C. Müller,T. Meyer,H. Watz
Physical activity is the strongest predictor of all-cause mortality in patients with COPD
Chest, 140 (2011), pp. 331-342 http://dx.doi.org/10.1378/chest.10-2521
155.
F. Pitta,T. Troosters,V.S. Probst,M.A. Spruit,M. Decramer,R. Gosselink
Quantifying physical activity in daily life with questionnaires and motion sensors in COPD
Eur Respir J, 27 (2006), pp. 1040-1055 http://dx.doi.org/10.1183/09031936.06.00064105
156.
H. Watz,B. Waschki,T. Meyer,H. Magnussen
Physical activity in patients with COPD
Eur Respir J, 33 (2009), pp. 262-272 http://dx.doi.org/10.1183/09031936.00024608
157.
J. García-Aymerich,I. Serra Pons,D.M. Mannino,A.K. Maas,D.P. Miller,K.J. Davis
Lung function impairment, COPD hospitalisations and subsequent mortality
158.
P.W. Jones,G. Harding,P. Berry,I. Wiklund,W.-H. Chen,N. Kline Leidy
Development and first validation of the COPD Assessment Test
Eur Respir J, 34 (2009), pp. 648-654 http://dx.doi.org/10.1183/09031936.00102509
159.
P. Jones,G. Harding,I. Wiklund,P. Berry,N. Leidy
Improving the process and outcome of care in COPD: development of a standardised assessment tool
Prim Care Respir J, 18 (2009), pp. 208-215 http://dx.doi.org/10.4104/pcrj.2009.00053
160.
P. Jones,M. Tabberer,W.G. Chen
Creating scenarios of the impact of COPD and their relationship to COPD asessment test (CATTM) socres
BMC Pulm Med, 11 (2011), pp. 42 http://dx.doi.org/10.1186/1471-2466-11-42
161.
P.W. Jones,G. Brusselle,R.W. Dal Negro,M. Ferrer,P. Kardos,M.L. Levy
Properties of the COPD assessment test in a cross-sectional European study
Eur Respir J, 38 (2011), pp. 29-35 http://dx.doi.org/10.1183/09031936.00177210
162.
N.R. Anthonisen,M.A. Skeans,R.A. Wise,J. Manfreda,R.E. Kanner,J.E. Connett
The effects of a smoking cessation intervention on 14,5-year mortality: a randomized clinical trial
Ann Intern Med, 142 (2005), pp. 233-239
163.
N.S. Godtfredsen,T.H. Lam,T.T. Hansel,M.E. Leon,N. Gray,C. Dresler
COPD related morbidity and mortality after smoking cessation: status of the evidence
Eur Respir J, 32 (2008), pp. 844-853 http://dx.doi.org/10.1183/09031936.00160007
164.
M.N. Hylkema,P.J. Sterk,W.I. De Boer,D.S. Postma
Tobacco use in relation to COPD and asthma
Eur Respir J, 29 (2007), pp. 438-445 http://dx.doi.org/10.1183/09031936.00124506
165.
E.J. Wagena,M.P.A. Zeegers,C.P. Van Schayck,E.F.M. Wouters
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease
Drug Saf, 26 (2003), pp. 381-403
166.
C.A. Jiménez Ruiz,J.I. De Granda Orive,J.A. Riesco Miranda
Abordaje diagnóstico y terapéutico del tabaquismo en EPOC
Tratado de rehabilitación respiratoria,
167.
C.A. Jiménez,F. Masa,M. Miravitlles,R. Gabriel,J.L. Viejo,C. Villasante
Smoking characteristics: attitudes and dependence. Differences between healthy smokers and smokers with COPD
Chest, 119 (2001), pp. 1365-1373
168.
M.C. Fiore,C.R. Jaén,T.G. Baker,W.C. Bailey,N.L. Benowitz,S.J. Curry
Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline
US Department of Health and Human Services, Public Health Service, (2008)
169.
D.P. Tashkin,S. Rennard,J. Taylor,Ma Wendy,D. Lawrence,T.C. Lee
Effects of varenicline on smoking cessation in patients with mild to moderate COPD. A randomized controlled trial
Chest, 139 (2011), pp. 591-599 http://dx.doi.org/10.1378/chest.10-0865
170.
D. Postma,A. Anzueto,P. Calverley,C. Jenkins,B.J. Make,F.C. Sciurba
A new perspective on optimal care for patients with COPD
Prim Care Respir J, 20 (2011), pp. 205-209 http://dx.doi.org/10.4104/pcrj.2011.00041
171.
P.J. Poole,E. Chacko,R.W. Wood-Baker,C.J. Cates
Influenza vaccine for patients with chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2006),
172.
B. Michiels,F. Govaerts,R. Remmen,E. Vermeire,S. Coenen
A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups
173.
J.A. Walters,S. Smith,P. Poole,R.H. Granger,R. Wood-Baker
Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2010),
174.
I. Alfageme,R. Vazquez,N. Reyes,J. Muñoz,A. Fernández,M. Hernandez
Clinical efficacy of anti-pneumococcal vaccination inpatients with COPD
175.
J.L. Lopez-Campos
Estrategias de tratamiento en la enfermedad pulmonar obstructiva crónica: una propuesta de sistematización
Arch Bronconeumol, 46 (2010), pp. 617-620 http://dx.doi.org/10.1016/j.arbres.2010.06.003
176.
P. Sestini,E. Renzoni,S. Robinson,P. Poole,F.S. Ram
Short-acting beta-2 agonists for stable chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2002),
177.
G. Boyd,A.H. Morice,J.C. Pounsford,M. Siebert,N. Peslis,C. Crawford
An evaluation of salmeterol in the treatment of the chronic obstructive pulmonary disease (COPD)
Eur Respir J, 10 (1997), pp. 815-821
178.
R. Aalbers,J. Ayres,V. Backer,M. Decramer,P.A. Lier,P. Magyar
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
Eur Respir J, 19 (2002), pp. 936-943
179.
R.A. Stockley,P.J. Whitehead,M.K. Williams
Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis
180.
D.P. Tashkin,C.B. Cooper
The role of long-acting bronchodilators in the management of stable COPD
Chest, 125 (2004), pp. 249-259
181.
J. Beier,K.M. Beeh
Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol
Int J Chron Obstruct Pulmon Dis, 6 (2011), pp. 237-243 http://dx.doi.org/10.2147/COPD.S7371
182.
V. Brusasco,R. Hodder,M. Miravitlles,L. Korducki,L. Towse,S. Kesten
Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD
Thorax, 58 (2003), pp. 399-404
183.
J. O’Donnell,T. Flüge,F. Gerken,A. Hamilton,K. Webb,B. Aguilaniu
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
Eur Respir J, 23 (2004), pp. 832-840
184.
W.D.C. Man,N. Mustfa,D. Nikoletou,S. Kaul,N. Hart,G.F. Rafferty
Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD
Thorax, 59 (2004), pp. 471-476
185.
B. Celli,M. Decramer,S. Kesten,D. Liu,S. Mehra,D.P. Tashkin
Mortality in the 4-year trial of Tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 180 (2009), pp. 948-955 http://dx.doi.org/10.1164/rccm.200906-0876OC
186.
M.A. Puhan,L.M. Bachmann,J. Kleijnen,G. Ter Riet,A.G. Kessels
Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis
187.
S. Appleton,T. Jones,P. Poole,L. Pilotto,R. Adams,T.J. Lasserson
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2006),
188.
S. Appleton,P. Poole,B. Smith,A. Veale,T.J. Lasserson,M.M. Chan
Long-acting beta-2 agonists for poorly reversible chronic obstructive pulmonary disease
Cochrane Database Syst Rev, 3 (2006), http://dx.doi.org/10.1002/14651858.CD009601.pub2
189.
T.J. Wilt,D. Niewoehner,R. MacDonald,R.L. Kane
management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline
Ann Intern Med, 147 (2007), pp. 639-653
190.
D.P. Tashkin,B. Celli,S. Senn,D. Burkhart,S. Kesten,S. Menjoge
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
N Engl J Med, 359 (2008), pp. 1543-1554 http://dx.doi.org/10.1056/NEJMoa0805800
191.
C. Vogelmeier,B. Hederer,T. Glaab,H. Schmidt,M.P.M.H. Rutten van Molkën,K.M. Beeh
Tiotropium versus salmeterol for the prevention of exacerbations of COPD
N Engl J Med, 364 (2011), pp. 1093-1103 http://dx.doi.org/10.1056/NEJMoa1008378
192.
R.G. Barr,J. Bourbeau,C.A. Camargo,F.S.F. Ram
Tiotropium for stable chronic obstructive pulmonary disease: a metaanalysis
193.
J.A. Van Noord,J.-L. Aumann,E. Janssens,J.J. Smeets,J. Verhaert,B. Disse
Comparison of tiotropium once daily, formoterol twice daily and both combined oncedaily in patients with COPD
Eur Respir J, 26 (2005), pp. 214-222 http://dx.doi.org/10.1183/09031936.05.00140404
194.
J.A. Van Noord,R. Buhl,C. LaForce,C. Martin,F. Jones,M. Dolker
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
Thorax, 65 (2010), pp. 1086-1091 http://dx.doi.org/10.1136/thx.2010.139113
195.
F.S.F. Ram,J.R. Jardim,A. Atallah
Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis
Respir Med, 99 (2005), pp. 135-144
196.
Y. Zhou,X. Wang,X. Zeng,R. Qiu,J. Xie,S. Liu
Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of lowdose, slow-release theophylline in the treatment of COPD for 1 year
197.
American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency
Am J Respir Crit Care Med, 168 (2003), pp. 818-900 http://dx.doi.org/10.1164/rccm.168.7.818
198.
Task Force on COPD
Moving towards a new focus on COPD. The Spanish COPD guidelines (GESEPOC)
Arch Bronconeumol, 47 (2011), pp. 379-381 http://dx.doi.org/10.1016/j.arbres.2011.05.008
199.
A. Papi,M. Romagnoli,S. Baraldo
Partial reversibility of airflow limitation and incresead exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 162 (2000), pp. 1773-1777 http://dx.doi.org/10.1164/ajrccm.162.5.9910112
200.
M. Miravitlles
Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity
Arch Bronconeumol, 47 (2011), pp. 271 http://dx.doi.org/10.1016/j.arbres.2011.01.016
201.
R. Siva,R.H. Green,C.E. Brightling,M. Shelley,B. Hargadon,S. McKenna
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Eur Respir J, 29 (2007), pp. 906-913 http://dx.doi.org/10.1183/09031936.00146306
202.
GEMA 2009
Guía Española para el Manejo del Asma 2009
Arch Bronconeumol, 45 (2009), pp. 2-35 http://dx.doi.org/10.1016/S0300-2896(09)73495-7
203.
T. Welte,M. Miravitlles,P. Hernandez,G. Eriksson,S. Peterson,T. Polanowski
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 180 (2009), pp. 741-750 http://dx.doi.org/10.1164/rccm.200904-0492OC
204.
S.P. Peters,S.J. Kunselman,M.A. Nikolina Icitovic,W.C. Moore,R. Pascual,B.T. Ameredes
Tiotropium bromide step-up therapy for adults with uncontrolled asthma
N Engl J Med, 363 (2010), pp. 1715-1726 http://dx.doi.org/10.1056/NEJMoa1008770
205.
American Thoracic Society
Standards for diagnosis and care of patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 152 (1995), pp. 77-121
206.
K.F. Rabe,S. Hurd,A. Anzueto,P.J. Barnes,S.A. Buist,P. Calverley
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary
Am J Respir Crit Care Med, 176 (2007), pp. 532-555 http://dx.doi.org/10.1164/rccm.200703-456SO
207.
P. Kardos,M. Wencker,T. Glaab,C. Vogelmeier
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 175 (2007), pp. 144-149 http://dx.doi.org/10.1164/rccm.200602-244OC
208.
W. Szafransky,A. Cukier,A. Ramirez,G. Menga,R. Sansores,S. Nahabedian
Efficacy and safety of budesonide/formoterol and formoterol in chronic obstructive pulmonary diseases
Eur Respir J, 21 (2003), pp. 74-81
209.
L.J. Nannini,C.J. Cates,T.J. Lasserson,P. Poole
Combined corticosteroid and longacting beta-agonistin one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2007),
210.
D.M. Sobieraj,C.M. White,C.I. Coleman
Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a metaanalysis
211.
A. Nieto,A. Mazon,R. Pamies
Adverse effects of inhaled corticosteroids in funded and nonfunded studies
Arch Intern Med, 167 (2007), pp. 2047-2053 http://dx.doi.org/10.1001/archinte.167.19.2047
212.
P.D. Scanlon,J.E. Connett,R.A. Wise
Loss of bone density with inhaled triamcinolone in Lung Health Study II
Am J Respir Crit Care Med, 170 (2004), pp. 1302-1309 http://dx.doi.org/10.1164/rccm.200310-1349OC
213.
P.M.A. Calverley,F. Sanchez-Toril,A. McIvor,P. Teichmann,D. Bredenbroeker,L.M. Fabbri
Effect of 1-year treatment with roflumilast in severe chronic obstructivepulmonary disease
Am J Respir Crit Care Med, 176 (2007), pp. 154-161 http://dx.doi.org/10.1164/rccm.200610-1563OC
214.
S.D. Aaron,K.L. Vandemheen,D. Fergusson,F. Maltais,J. Bourbeau,R. Goldstein
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial
Ann Intern Med, 146 (2007), pp. 545-555
215.
C. Karner,C.J. Cates
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease
Cochrane Database of Systematic Reviews, (2011),
216.
P.J. Barnes
Theophylline for COPD
217.
B.G. Cosio,L. Tsaprouni,K. Ito,E. Jazrawi,I.M. Adcock,P.J. Barnes
Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages
J Exp Med, 200 (2004), pp. 689-695 http://dx.doi.org/10.1084/jem.20040416
218.
L.M. Fabbri,P.M.A. Calverley,J.L. Izquierdo-Alonso,D.S. Bundschuh,M. Brose,F.J. Martinez
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials
219.
E.D. Bateman,K.F. Rabe,P.M.A. Calverley,U.M. Goehring,M. Brose,D. Bredenbroker
Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history
Eur Respir J, 38 (2011), pp. 553-560 http://dx.doi.org/10.1183/09031936.00178710
220.
S.I. Rennard,P.M.A. Calverley,U.M. Goehring
Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD
221.
E.M. Grandjean,P. Berthet,R. Ruffmann,M. Leuenberger
Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a metaanalysis of published double-blind, placebo-controlled clinical trials
222.
E.R. Sutherland,J.D. Crapo,R.P. Bowler
N-Acetylcysteine and exacerbations of chronic obstructive pulmonary disease
COPD, 3 (2006), pp. 195-202
223.
P.J. Poole,P.N. Black
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2006),
224.
J.P. Zheng,J. Kang,S.G. Huang
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebocontrolled study
225.
M. Decramer,M.M. Rutten-van,P.N. Dekhuijzen,T. Troosters,C. Van Herwaarden,R. Pellegrion
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study. BRONCUS): a randomized placebo-controlled trial
226.
T. Staykova,P.N. Black,E.E. Chacko,P. Poole
Prophylactic antibiotic therapy for chronic bronchitis
Cochrane Review, (2009),
227.
D. Sevilla-Sánchez,D. Soy-Muner,N. Soler-Porcar
Utilidad de los macrólidos como antiinflamatorios en las enfermedades respiratorias
Arch Bronconeumol, 46 (2010), pp. 244-254 http://dx.doi.org/10.1016/j.arbres.2009.10.008
228.
T.A.R. Seemungal,T.M.A. Wilkinson,J.R. Hurst,W.R. Perera,R.J. Sapsford,J.A. Wedzicha
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations
Am J Respir Crit Care Med, 178 (2008), pp. 1139-1147 http://dx.doi.org/10.1164/rccm.200801-145OC
229.
X. Pomares,C. Montón,M. Espasa,J. Casabon,E. Monsó,M. Gallego
Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations
Int J Chron Obst Respir Dis, 6 (2011), pp. 449-456
230.
R.K. Albert,J. Connett,W.C. Biley,R. Casaburi,J.A.D. Cooper,G.J. Criner
Azithromycin for prevention of exacerbations of COPD
N Engl J Med, 365 (2011), pp. 689-698 http://dx.doi.org/10.1056/NEJMoa1104623
231.
M. Miravitlles,A. Marín,E. Monsó,S. Vilà,C. De la Roza,R. Hervás
Efficacy of moxifloxacin in the treatment of bronchial colonization in COPD
Eur Respir J, 34 (2009), pp. 1066-1071 http://dx.doi.org/10.1183/09031936.00195608
232.
S. Sethi,P.W. Jones,M.S. Theron,M. Miravitlles,E. Rubinstein,J.A. Wedzicha
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial
233.
S. Sethi,T.F. Murphy
Infection in the pathogenesis and course of chronic obstructive pulmonary disease
N Engl J Med, 359 (2008), pp. 2355-2365 http://dx.doi.org/10.1056/NEJMra0800353
234.
S.G. Adams,A. Anzueto,D.D. Briggs Jr.,I. Leimer,S. Kesten
Evaluation of withdrawal of maintenance tiotropium in COPD
Respir Med, 103 (2009), pp. 1415-1420 http://dx.doi.org/10.1016/j.rmed.2009.05.018
235.
P. Van der Valk,E. Monninkhof,J. Van del Palen,G. Zielhuis,C. Van Herwaarden
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study
Am J Respir Crit Care Med, 166 (2002), pp. 1358-1363 http://dx.doi.org/10.1164/rccm.200206-512OC
236.
J. Nighat,N.J. Nadeem,S. Taylor,S.M. Eldridge
Withdrawal of inhaled corticosteroids in individuals with COPD: a systematic review and comment on trial methodology
237.
T.R.J. Schermer,A.J.C. Hendriks,N.H. Chavannes,P.N.R. Dekhuijzen,E.F.M. Wouters,H. Van der Hoogen
probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice
Prim Care Respir J, 13 (2004), pp. 48-55 http://dx.doi.org/10.1016/j.pcrj.2003.11.005
238.
J.J.W. Liesker,E. Bathoorn,D.S. Postma,J.M. Vonk,W. Timens,H.A.M. Kerstjens
Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD
Respir Med, 105 (2011), pp. 1853-1860 http://dx.doi.org/10.1016/j.rmed.2011.07.002
239.
J.M. Cranston,A.J. Crockett,J.R. Moss,J.H. Alpers
Domiciliary oxygen for COPD
Cochrane Database Syst Rev, (2005),
240.
Report of Medical Research Council Working Party
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema
Lancet, (1981), pp. 681-686
241.
Nocturnal Oxygen Therapy Trial Group
Continuous of nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease
An Intern Med, 93 (1980), pp. 391-398
242.
V. Kim,J.O. Benditt,R.A. Wise,A. Sharafkhaneh
Oxygen therapy in chronic obstructive pulmonary disease
Proc Am Thorac Soc, 5 (2008), pp. 513-518 http://dx.doi.org/10.1513/pats.200708-124ET
243.
E. Chailleux,B. Fauroux,F. Bidet,B. Dautzenberg,J.M. Polu
Predictors of survival in patients receiving domiciliary oxigen therapy or mechanical ventilation. A 10- year analysis of ANTADIR Observatory
Chest, 109 (1996), pp. 741-749
244.
D.E. O’Donell,C. D’Arsigny,K.A. Webb
Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 163 (2001), pp. 892-898 http://dx.doi.org/10.1164/ajrccm.163.4.2007026
245.
P.J. Wijkstra,G.H. Guyatt,N. Ambrosino,B.R. Celli,R. Güell,J.F. Muir
International approaches to the prescription of long-term oxygen therapy
Eur Respir J, 18 (2001), pp. 909-913
246.
Atención integral al paciente con EPOC
Desde la Atención Primaria a la Especializada
Guía de práctica clínica, (2010),
247.
Guía de práctica clínica de diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. SEPAR-ALAT, 2009.
248.
J.M. Bradley,T. Lasserson,S. Elborn,J. Macmahon,B. O’Neill
A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD
Chest, 131 (2007), pp. 278-285 http://dx.doi.org/10.1378/chest.06-0180
249.
J.M. Bradley,B. O’Neill
Short-term ambulatory oxygen for chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2005),
250.
M.A. Kolodziej,L. Jensen,B. Rowe,D. Sin
Systematic review of noninvasive positive pressure ventilation in severe stable COPD
Eur Respir J, 30 (2007), pp. 293-306 http://dx.doi.org/10.1183/09031936.00145106
251.
R.D. McEvoy,R.J. Pierce,D. Hillman
Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial
252.
S. Budweiser,R.A. Jörres,M. Pfeifer
Treatment of respiratory failure in COPD
Int J COPD, 3 (2008), pp. 605-618
253.
A. Goldberg,P. Leger,N. Hill,G. Criner
Clinical indications for non-invasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease. OPD, and nocturnal hypoventilation. A consensus conference report
Chest, 116 (1999), pp. 521-534
254.
P.C. Gay
UptoDate
Nocturnal ventilatory support in COPD, (2011),
255.
L. Nice,C.I. Donner,E. Wouters
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation
Am J Respir Crit Care Med, 173 (2006), pp. 1390-1413 http://dx.doi.org/10.1164/rccm.200508-1211ST
256.
ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel
Pulmonary rehabilitation. Joint ACCP/AACVPR Evidence-Based Guidelines
257.
R. Güell,V. Resqueti,M. Sangenis
Impact of pulmonary rehabilitation on pshychosocial morbidity in patients with severe chronic obstructive pulmonary disease
258.
Y. Lacasse,R. Goldstein,T.J. Lasserson,S. Martin
Pulmonary rehabilitation for chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2006),
259.
F. Lötters,B. Van Tol,G. Kwakkel
Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis
Eur Respir J, 20 (2002), pp. 570-576
260.
British Thoracic Society
Standards of care subcommittee on pulmonary rehabilitation
Thorax, 56 (2001), pp. 827-834
261.
M.K. Beauchamp,T. Janaudis-Ferreira,R.S. Goldstein,D. Brooks
Optimal duration of pulmonary rehabilitation for individuals with chronic obstructive pulmonary disease: a systematic review
Chron Respir Dis, 8 (2011), pp. 129-140 http://dx.doi.org/10.1177/1479972311404256
262.
A. Qaseem,T.J. Wilt,S.E. Weinberger,N.A. Hanania,G. Criner,T. Van der Molen
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians. American Thoracic Society, and European Respiratory Society
263.
D.D. Marciniuk,D. Brooks,S. Butcher,R. Debigare,G. Dechman,G. Ford,Canadian Thoracic Society COPD Committee Expert Working Group
Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease--practical issues: a Canadian Thoracic Society Clinical Practice Guideline
Can Respir J, 17 (2010), pp. 159-168
264.
N. Hopkinson,M. Polkey
Does physical inactivity cause chronic obstructive pulmonary disease?
Clin Sci, 118 (2010), pp. 565-572 http://dx.doi.org/10.1042/CS20090458
265.
G. Grandes,A. Sánchez,R.O. Sánchez-Pinilla,J. Torcal,I. Montoya,K. Lizarraga,PEPAF Group
Effectiveness of physical activity advice and prescription by physicians in routine primary care: a cluster randomized trial
Arch Intern Med, 169 (2009), pp. 694-701 http://dx.doi.org/10.1001/archinternmed.2009.23
266.
M.H. Ussher,A. Taylor,G. Faulkner
Exercise interventions for smoking cessation
Cochrane Database Syst Rev, (2008),
267.
M. Juan Díaz,A. Serrano Lázaro,A. Mesejo Arizmendi
Aspectos nutricionales de la patología pulmonar
Nutr Clin Med, 2 (2008), pp. 141-154
268.
S. Alcolea Batres,J. Villamor León,R. Álvarez-Sala
EPOC y estado nutricional
Arch Bronconeumol, 43 (2007), pp. 283-288
269.
C. Martín Salinas,T. Motilla Valeriano,Valoración del estado nutricional
Nutrición y Dietética, 2.ª, pp. 301-319
270.
A. Martín Zurro,J.F. Cano Pérez
Atención primaria: conceptos, organización y práctica clínica, pp. 991-1006
271.
F.J. Martinez
Bullectomy for giant bullae in COPD, (2011),
272.
T.D. Christie,L.B. Edwards,P. Aurora,F. Dobbels,R. Kirk,A.O. Rahmel
Registry of the Internacional Society for Heart and Lung Transplantation Report-2008
J Heart Lung Transplant, 27 (2008), pp. 957-969 http://dx.doi.org/10.1016/j.healun.2008.07.018
273.
S. Lahzami,J.D. Aubert
Lung transplantation for COPD- evidence-based?
Swiss Med WKI, 139 (2009), pp. 4-8
274.
Normativa para la selección de pacientes candidatos a trasplante pulmonar
Arch Bronconeumol, 47 (2011), pp. 303-309 http://dx.doi.org/10.1016/j.arbres.2011.03.007
275.
F.J. Martinez
Lung volume reduction surgery in COPD. Uptodate, (2011),
276.
J. Reilly,G. Waskho,V. Pinto-Plata,E. Velez,L. Kenney,R. Berger
Biological lung volume reduction:a new bronchoscopic therapy for advance emphysema
Chest, 131 (2007), pp. 1108-1113 http://dx.doi.org/10.1378/chest.06-1754
277.
R.L. Berger,M.M. Decamp,G.J. Criner,B.R. Celli
Lung volume reduction therapies for advanced emphysema: an update
Chest, 138 (2010), pp. 407-417 http://dx.doi.org/10.1378/chest.09-1822
278.
National Emphysema Treatment Trial Research Group
Rationale and desing of the National Emphysema Treatment trial (NETT): a prospective randomized trial of lung volumen reduction surgery
J Thorac Cardiovasc Surg, 118 (1999), pp. 518-528
279.
National Emphysema Treatment Trial Research
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
N Engl J Med, 348 (2003), pp. 2059-2073 http://dx.doi.org/10.1056/NEJMoa030287
280.
M.R. Güell,M.P. Cejudo,G. Rodríguez-Trigo,J.B. Gáldiz,V. Casolive,M. Reguerio
Estándares de calidad asistencial en rehabilitación respiratoria en pacientes con enfermedad pulmonar crónica
Arch Bronconeumol, (2012),
281.
F. De Blasio,M. Polverino
Current best practice in pulmonary rehabilitation for chronic obstructive pulmonary disease. Ther Adv Respir Dis
PMID, (2012), pp. 22563010
282.
T.A.R. Seemungal,G.C. Donaldson,E.A. Paul,J.C. Bestall,D.J. Jeffries,J.A. Wedzicha
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 157 (1998), pp. 1418-1422 http://dx.doi.org/10.1164/ajrccm.157.5.9709032
283.
L. Langsetmo,R.W. Platt,P. Ernst,J. Bourbeau
Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort
Am J Respir Crit Care Med, 177 (2008), pp. 396-401 http://dx.doi.org/10.1164/rccm.200708-1290OC
284.
M. Miravitlles,M. Ferrer,A. Pont,R. Zalacaín,J.L. Álvarez-Sala,J.F. Masa,for the IMPAC study group
Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study
Thorax, 59 (2004), pp. 387-395
285.
J.R. Hurst,G.C. Donaldson,W.R. Perera,T.M. Wilkinson,J.A. Bilello,G.W. Hagan
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease
Am J Respir Crit Care Med, 174 (2006), pp. 867-874 http://dx.doi.org/10.1164/rccm.200604-506OC
286.
C.M. Parker,N. Voduc,S.D. Aaron,K.A. Webb,D.E. O’Donnell
Physiologic changes during symptom recovery from moderate exacerbation of COPD
Eur Respir J, 26 (2005), pp. 420-428 http://dx.doi.org/10.1183/09031936.05.00136304
287.
W.R. Perera,J.R. Hurst,T.M.A. Wilkinson,R.J. Sapsford,H. Müllerova,G.C. Donaldson
Inflammatory changes, recovery and recurrence at COPD exacerbation
Eur Respir J, 29 (2007), pp. 527-534 http://dx.doi.org/10.1183/09031936.00092506
288.
J.J. Soler-Cataluña,M.A. Martínez-García,P. Román-Sanchez,E. Salcedo,M. Navarro,R. Ochando
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
289.
F. Abroug,L. Quanes-Besbes,N. Nciri,N. Sellami,F. Addad,K. Ben Hamda
Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disaase. Diagnostic performance of cardiac biomarkers
Am J Respir Crit Care Med, 174 (2006), pp. 990-996 http://dx.doi.org/10.1164/rccm.200603-380OC
290.
C.L. Chang,S.C. Robinson,G.D. Mills,G.D. Sullivan,N.C. Karalus,J.D. McLachlan
Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD
291.
E. Sapey,A. Stockley
COPD exacerbations: aetiology
292.
A. Papi,C.M. Bellettato,F. Braccioni,M. Romagnoli,P. Casolari,G. Caramori
Infections of airway inflammation in chronic obstructive pulmonary disease severe exacerbations
Am J Respir Crit Care Med, 173 (2006), pp. 1114-1121 http://dx.doi.org/10.1164/rccm.200506-859OC
293.
M. Miravitlles,C. Espinosa,E. Fernández-Laso,J.A. Martos,J.A. Maldonado,M. Gallego,and Study Group of Bacterial Infection in COPD
Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD
Chest, 116 (1999), pp. 40-46
294.
N.R. Anthonisen,J. Manfreda,C.P. Warren,E.S. Hershfield,G.K. Harding,N.A. Nelson
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
Ann Intern Med, 106 (1987), pp. 196-204
295.
R.A. Stockley,C. O’Brien,A. Pye,S.L. Hill
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD
Chest, 117 (2000), pp. 1638-1645
296.
N. Soler,C. Agustí,J. Angrill,J. Puig de la Bellacasa,A. Torres
Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease
297.
S. Tokmas,P. Schuetz,S. Bent
Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations
Expert Rev Anti Infect Ther, 9 (2011), pp. 727-735 http://dx.doi.org/10.1586/eri.11.45
298.
J.M. Daniels,M. Schoorl,D. Snijders
Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD
Chest, 138 (2010), pp. 1108-1115 http://dx.doi.org/10.1378/chest.09-2927
299.
J. Rizkallah,S.F. Man,D.D. Sin
Prevalence of pulmonary embolism in acute exacerbation of COPD: a systematic review and metaanalysis
Chest, 135 (2009), pp. 786-793 http://dx.doi.org/10.1378/chest.08-1516
300.
F. Uresandi,J. Blanquer,F. Conget,M.A. De Gregorio,J.L. Lobo,R. Otero
Guía para el diagnóstico, tratamiento y seguimiento de la tromboembolia pulmonar
Arch Bronconeumol, (2004), pp. 580-594
301.
D.C. McCrory,C. Brown,S.E. Gelfand,P.B. Bach
Management of acute exacerbations of COPD: a summary and appraisal of published evidence
Chest, 119 (2001), pp. 1190-1209
302.
M.O. Turner,A. Patel,S. Ginsburg,J.M. FitzGerald
Bronchodilator delivery in acute airflow obstruction. A meta-analysis
Arch Intern Med, 157 (1997), pp. 1736-1744
303.
J. Boe,J.H. Dennis,B.R. O’Driscoll
European Respiratory Society Guidelines on the use of nebulizers
Eur Respir J, 18 (2001), pp. 228-242
304.
F. Di Marco,M. Verga,P. Santus,N. Morelli,M. Cazzola,S. Centanni
Effect of formoterol, tiotropium, and their combination in patients with acute exacerbations of chronic obstructive pulmonary disease: a pilot study
Respir Med, 100 (2006), pp. 1925-1932 http://dx.doi.org/10.1016/j.rmed.2006.03.007
305.
R.G. Barr,B.H. Rowe,C.A. Camargo
Methylxanthines for exacerbations of chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2003),
306.
S. Nouira,S. Marghli,M. Belghith,L. Besbes,S. Elatrous,F. Abroug
Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial
307.
M. Miravitlles,E. Monsó,J. Mensa,J. Aguarón Pérez,J. Barberán,M. Bárcena Caamaño
Tratamiento antimicrobiano de la agudización de EPOC: Documento de Consenso 2007
Arch Bronconeumol, 44 (2008), pp. 100-108
308.
J.M. Singh,V.A. Palda,M.B. Stanbrook,K.R. Chapman
Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review
Arch Intern Med, 162 (2002), pp. 2527-2536
309.
J.A. Walters,P.G. Gibson,R. Wood-Baker,M. Hannay,E.H. Walters
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2009),
310.
R.K. Albert,T.R. Martin,S.W. Lewis
Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency
Ann Intern Med, 92 (1980), pp. 753-758
311.
L. Davies,R.M. Angus,P.M. Calverley
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial
Lancet, 354 (1999), pp. 456-460
312.
H. Gunen,S.S. Hacievliyagil,O. Yetkin,G. Gulban,L.C.E. Mutly
The role of neublized budesonide in the treatment of exacerbations of COPD
Eur Respir J, 29 (2007), pp. 660-667 http://dx.doi.org/10.1183/09031936.00073506
313.
F. Maltais,J. Ostinelli,J. Bourbeau,A.B. Tonnel,N. Jacquemet,J. Haddon
Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial
Am J Respir Crit Care Med, 165 (2002), pp. 698-703 http://dx.doi.org/10.1164/ajrccm.165.5.2109093
314.
R. Otero,E. Grau,D. Jiménez,F. Uresandi,J.L. López,E. Calderón
Profilaxis de la enfermedad tromboémbólica venosa
Arch Bronconeumol, 44 (2008), pp. 160-169
315.
M.A. Puhan,E. Gimeno-Santos,M. Scharplatz,T. Troosters,E.H. Walters,J. Steurer
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
Cochrane Database Syst Rev, (2011),
316.
C. Burtin,M. Decramer,R. Gosselink,W. Janssens,T. Troosters
Rehabilitation and acute exacerbations
Eur Respir Dis, 38 (2011), pp. 702-712
317.
J.V. Lightowler,J.A. Wedzicha,M.W. Elliott,F.S. Ram
Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis
Br Med J, 326 (2003), pp. 185-187
318.
C. Hernandez,A. Casas,J. Escarrabill,J. Alonso,J. Puig-Junoy,E. Farrero
Home hospitalization of exacerbated chronic obstructive pulmonary disease patients
Eur Respir J, 21 (2003), pp. 58-67
319.
F.S. Ram,J.A. Wedzicha,J. Wright,M. Greenstone
Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence
Br Med J, 329 (2004), pp. 315
320.
National Cancer Institute. Disponible en: http://www.cancer.gov/.
321.
J.R. Curtis
Palliative and end-of-life care for patients with severe COPD
Eur Respir J, 32 (2008), pp. 796-803 http://dx.doi.org/10.1183/09031936.00126107
322.
J.S. Temel,J.A. Greer,A. Muzikansky
Early palliative care for patients with metastatic non-small-cell lung cancer
N Engl J Med, 363 (2010), pp. 733-742 http://dx.doi.org/10.1056/NEJMoa1000678
323.
J.M. Gore,C.J. Brophy,M.A. Greenstone
How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)?. A comparison of palliative care and quality of life in COPD and lung cancer
Thorax, 55 (2000), pp. 1000-1006
324.
K.E. Steinhauser,R.M. Arnold,M.K. Olsen,J. Lindquist,J. Hays,L.L. Wood
Comparing three life-limiting diseases: does diagnosis matter or is sick, sick?
J Pain Symptom Manage, 42 (2011), pp. 331-341 http://dx.doi.org/10.1016/j.jpainsymman.2010.11.006
325.
C. Bausewein,S. Booth,M. Gysels
Understanding breathlessness: crosssectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer
J Palliat Med, 13 (2010), pp. 1109-1118 http://dx.doi.org/10.1089/jpm.2010.0068
326.
V. Lohne,H.C. Heer,M. Andersen
Qualitative study of pain of patients with chronic obstructive pulmonary disease
327.
R. Horton,G. Rocker
Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease
Curr Opin Support Palliat Care, 4 (2010), pp. 56-62 http://dx.doi.org/10.1097/SPC.0b013e328338c1c6
328.
H. Pinnock,M. Kendall,S.A. Murray
Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study
Br Med J, (2011), pp. d142
329.
N. Small,C. Gardiner,S. Barnes
Using a prediction of death in the next 12 months as a prompt for referral to palliative care acts to the detriment of patients with heart failure and chronic obstructive pulmonary disease
330.
K. Hardin,F. Meyers,S. Louie
Integrating palliative care in severe chronic obstructive lung disease
331.
C. Bausewein,S. Booth,M. Gysels,I. Higginson
Nonpharmacological interventions for breathlessness in advanced stages of malignant and nonmalignant diseases
Cochrane Database Syst Rev, (2008),
332.
A.L. Jennings,A.N. Davies,J.P. Higgins
A systematic review of the use of opioids in the management of dyspnoea
Thorax, 57 (2002), pp. 939-944
333.
A.P. Abernethy,D.C. Currow,P. Frith
Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea
Br Med J, 327 (2003), pp. 523-528
334.
A.L. Jennings,A.N. Davies,J.P.T. Higgins,K. Broadley
Tratamiento paliativo con opiáceos para la disnea de la enfermedad terminal (Revisión Cochrane traducida). Biblioteca Cochrane Plus
Update Software Ltd, (2008)
335.
D. Goodridge,J. Lawson,G. Rocker,D. Marciniuk,D. Rennie
Factors associated with opioid dispensation for patients with COPD and lung cancer in the last year of life: a retrospective analysis
Int J Chron Obstruct Pulmon Dis, 5 (2010), pp. 99-105
336.
B. Varkey
Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients
Curr Opin Pulm Med, 16 (2010), pp. 150-154 http://dx.doi.org/10.1097/MCP.0b013e3283364378
337.
S.T. Simon,I.J. Higginson,S. Booth
Benzodiazepinas para el alivio de la disnea en adultos con enfermedades malignas y benignas. Biblioteca Cochrane Plus
Update Software Ltd, (2010)
338.
H. Putman-Casdorph,S. McCrone
Chronic obstructive pulmonary disease, anxiety, and depression: state of the science
339.
Sociedad Española de Cuidados Paliativos. Cuidados paliativos: la familia de la persona enferma. Disponible en: http://www.secpal.com/guiasm/index. php?acc=see_guia&id_guia=4.
340.
Normativas SEPAR: Recomendaciones sobre la atención al final de la vida en pacientes con EPOC. Disponible en: http://www.separ.es/publicaciones/normativa/normativa_052.html.
341.
J. Escarrabill,J.J. Soler Cataluña,C. Hernández
Recommendations for End-of- Life Care in Patients With Chronic Obstructive Pulmonary Disease
Arch Bronconeumol, 45 (2009), pp. 297-303 http://dx.doi.org/10.1016/j.arbres.2008.11.005
342.
M.E. Romero Roy,J.F. Jimeno Salgado
Yoga y EPOC. Abordaje desde las técnicas respiratorias
Medicina Naturista, (2007), pp. 30-35
343.
W. Hutton
Putting the public at the heart of the NHS
Br Med J, 334 (2007), pp. 69-70
344.
Health literacy: report of the Council on Scientific Affairs
Ad Hoc Committee on Health Literacy for the Council on Scientific Affairs, American Medical Association
JAMA, 281 (1999), pp. 552-557
345.
D.A. Dewalt,N.D. Berkman,S. Sheridan,K.N. Lohr,M.P. Pignone
Literacy and health outcomes: a systematic review of the literature
J Gen Intern Med, 19 (2004), pp. 1228-1239 http://dx.doi.org/10.1111/j.1525-1497.2004.40153.x
346.
C.R. Selden,M. Zorn,S.C. Ratzan
Health literacy, (2011),
347.
D.A. Dewalt,M.P. Pignone
The role of literacy in health and health care
Am Fam Physician, 72 (2005), pp. 387-388
348.
P. Easton,V.A. Entwistle,B. Williams
Health in the ‘hidden population’ of people with low literacy. A systematic review of the literature
BMC Public Health, 10 (2010), pp. 459 http://dx.doi.org/10.1186/1471-2458-10-459
349.
B.J. Powers,J.V. Trinh,H.B. Bosworth
Can this patient read and understand written health information?
350.
N.J. Roberts,R. Ghiassi,M.R. Partridge
Health literacy in COPD
Int J Chron Obstruct Pulmon Dis, 3 (2008), pp. 499-507
351.
T.C. Davis,M.S. Wolf
Health literacy: implications for family medicine
Fam Med, 36 (2004), pp. 595-598
352.
D.W. Baker,R.M. Parker,M.V. Williams,K. Pitkin,N.S. Parikh,W. Coates
The health care experience of patients with low literacy
Arch Fam Med, 5 (1996), pp. 329-334
353.
R.S. Safeer,J. Keenan
Health literacy: the gap between physicians and patients
Am Fam Physician, 72 (2005), pp. 463-468
354.
S.G. Adams,P.K. Smith,P.F. Allan,A. Anzueto,J.A. Pugh,J.E. Cornell
Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management
Arch Intern Med, 167 (2007), pp. 551-561 http://dx.doi.org/10.1001/archinte.167.6.551
355.
J. Bourbeau,J. Van der Palen
Promoting effective self-management programmes to improve COPD
Eur Respir J, 33 (2009), pp. 461-463 http://dx.doi.org/10.1183/09031936.00001309
356.
T. Bodenheimer,K. MacGregor,C. Sharifi
Helping patients manage their chronic conditions
California Healthcare Foundation, (2005)
357.
L.B. Mauksch,D.C. Dugdale,S. Dodson,R. Epstein
Relationship, Communication, and Efficiency in the Medical Encounter
Arch Intern Med, 168 (2008), pp. 1387-1395 http://dx.doi.org/10.1001/archinte.168.13.1387
358.
W. Langewitz,M. Denz,A. Keller,A. Kiss,S. Rüttimann,B. Wössmer
Spontaneous talking time at start of consultation in outpatient clinic: cohort study
Br Med J, 325 (2002), pp. 682-683
359.
J.L. Hanson
Shared decision making. Have we missed the obvious?
Arch Intern Med, 168 (2008), pp. 1368-1370 http://dx.doi.org/10.1001/archinte.168.13.1368
360.
J. Bourbeau,M. Julien,F. Maltais,M. Rouleau,A. Beaupré,R. Bégin
Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention
Arch Intern Med, 163 (2003), pp. 585-591
361.
B. De Vries,C. Darling-Fisher,A.C. Thomas,E.B. Belanger-Shugart
Implementation and outcomes of group medical appointments in an outpatient specialty care clinic
J Am Acad Nurse Pract, 20 (2008), pp. 163-169 http://dx.doi.org/10.1111/j.1745-7599.2007.00300.x
362.
R. Jaber,A. Braksmajer,J. Trilling,Group visits for chronic illness care: models, benefits and challenges
Fam Pract Manag, 13 (2006), pp. 37-40
363.
E.W. Bischoff,D.H. Hamd,M. Sedeno,A. Benedetti,T.R. Schermer,S. Bernard
Effects of written action plan adherence on COPD exacerbation recovery
364.
Universidad de los pacientes [accedido 7 May 2011]. Disponible en: http://www.universidadpacientes.org/kitdevisitamedica/elkit/index.php?pag=descarga.
365.
A. Jovell,M. Navarro Rubio,L. Fernández Maldonado,S. Blancafort
Nuevo rol del paciente en el sistema sanitario
Aten Primaria, 38 (2006), pp. 234-237
366.
The Expert Patient A New Approach to Chronic Disease Managementfor the 21st Century [accedido 8 May 2011]. Disponible en: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4018578.pdf.
367.
A. González Mestre,N. Fabrellas Padrés,M. Agramunt Perelló,E. Rodríguez Pérez,E. Grifell Martín
De paciente pasivo a paciente activo
Programa Paciente Experto del Institut Català de la Salut. Revista de Innovación Sanitaria y Atención Integrada, 1 (2008),
368.
K. Lorig
Partnerships between expert patients and physicians
369.
K.R. Lorig,P.L. Ritter,A. Dost,K. Plant,D.D. Laurent,I. McNeil
The Expert Patients Programme online, a 1-year study of an Internet-based self-management programme for people with long-term conditions
Chronic Illn, 4 (2008), pp. 247-256 http://dx.doi.org/10.1177/1742395308098886
370.
M. Martí,N. Fabrellas,S. Chicote,V. Escribano,A. Raventós,N. Padilla
Llamada al autocuidado. Seguimiento telefónico a enfermedades crónicas
Revista de Innovación Sanitaria y Atención Integrada, 1 (2008),
371.
A. Marshall,O. Medvedev,A. Antonov
Use of a smartphone for improved selfmanagement of pulmonary rehabilitation
Int J Telemed Appl, 75 (2008), pp. 30-64
372.
P. De Toledo,S. Jiménez,F. Del Pozo,J. Roca,A. Alonso,C. Hernandez
Telemedicine experience for chronic care in COPD
IEEE Transactions on Information Technology in Biomedicine, 10 (2006), pp. 567-573
373.
E. Torrente,J. Escarrabill,T. Martí
Impacto de las redes sociales de pacientes en la práctica asistencial
Revista de Innovación Sanitaria y Atención Integrada, 2 (2010),
374.
D. Tapscott,D. Williams
Wikinomics
Atlantic Books, (2006)
Copyright © 2012. Sociedad Española de Neumología y Cirugía Torácica
Arch Bronconeumol 2012;48 Supl 1:2-58 - Vol. 48 DOI: 10.1016/S0300-2896(12)70035-2